UNSPSC 51383704: Naproxol

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33S398GAY6. European Medicines Agency schedules Naproxol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09160MIG. Naproxol generally arises in the molecular formula C14H16O2.

The term NAPROXOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, no. 10 1971, list 11.) NAPROXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule naproxol under HS 29094990 and SITC 51617. As of Q4 2014, NAPROXOL remains the US FDA Preferred Term for this commodity. Naproxol bears US NLM identifiers UMLS ID C2827277 and NCI Concept Code C83990. SMILES: OCC(C1CC2C(CC1)CC(OC)CC2)C.

UNSPSC 51383704 Naproxol is a Commodity code that captures pharmaceutical products state and local governments procure for community health, emergency response, and pharmacy benefit programs. Recent state and local solicitations show activity extending beyond naproxol specifically to naloxone, generic multi-source pharmaceuticals, and over-the-counter products distributed through established healthcare channels and cooperative purchasing networks. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that coordinate procurement across participating state agencies and local government facilities. The scope spans direct pharmaceutical supply (unit purchases for quarterly delivery to health facilities), participation in statewide pharmacy benefit programs, and fulfillment through authorized drug wholesalers with compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, and specific insurance and E-Verify mandates.

Recent activity centers in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program intended to inform future formal solicitation strategy. The Minnesota Department of Administration, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendor pricing for identified products through three authorized wholesalers and effective July 1, 2026. MMCAP contracts carry a two-year initial term with optional extensions and a 3 percent administrative fee on all contract purchases.